That sounds like a Phase 1 trial for safety in human volunteers. If the plan was to sell the IP to or partner with a major Pharma, maybe this could work. But the IP situation may not be that clear-cut with a drug repurposing, especially given this:
> This is still a tall order for a guy whose background was, again, science blogger. But things went surprisingly ok, all things considered. I linked up with an excellent corporate attorney and patent attorney, both of whom agreed to let me use their services on a pay later basis. ...
You really can't do this on the cheap.
People in tech (or even science broadly) trying to get into the drug industry frankly have no clue about what it actually takes to get a drug approved for humans in the US. Hundreds of millions are table stakes. The bar is higher than just about any other industry for new product introduction, even for a repurposing.
Even if the bear market had stayed in hibernation for another year or two, the fundamental problem is that human drug approval is a massive resource drain that requires very deep pockets and an ironclad IP position.
Failure (after massive expenditure) should be considered the base case.